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Background: Cancer-associated fibroblasts and high mobility group box 1 (HMGB1) protein have been suggested
to mediate cancer progression and chemotherapy resistance. The role of such fibroblasts in HMGB1 production in
breast cancer is unclear. This study aimed to investigate the effects of cancer-associated fibroblasts on HMGB1
expression in breast cancer cells and its role in chemotherapeutic response.
Methods: Breast cancer-associated fibroblasts (BCFs) and non-tumor-associated fibroblasts (NTFs) were isolated from
human breast cancers or adjacent normal tissues and established as primary cultures in vitro. After confirmation of
the activated status of these fibroblasts, conditioned-media (CM) were collected and applied to MDA-MB-231 human
triple negative breast cancer cells. The levels of intracellular and extracellular HMGB1 were measured by real-time PCR
and/or Western blot. The response of BCF-CM-pre-treated cancer cells to doxorubicin (Dox) was compared with those
pre-treated with NTF-CM or control cultures. The effect of an HMGB1 neutralizing antibody on Dox resistance induced
by extracellular HMGB1 from non-viable Dox-treated cancer cells or recombinant HMGB1 was also investigated.
Results: Immunocytochemical analysis revealed that BCFs and NTFs were alpha-smooth muscle actin (ASMA) positive
and cytokeratin 19 (CK19) negative cells: a phenotype consistent with that of activated fibroblasts. We confirmed that
the CM from BCFs (but not NTFs), could significantly induce breast cancer cell migration. Intracellular HMGB1 expression
was induced in BCF-CM-treated breast cancer cells and also in Dox-treated cells. Extracellular HMGB1 was strongly
expressed in the CM after Dox-induced MDA-MB-231 cell death and was higher in cells pre-treated with BCF-CM than
NTF-CM. Pre-treatment of breast cancer cells with BCF-CM induced a degree of resistance to Dox in accordance
with the increased level of secreted HMGB1. Recombinant HMGB1 was shown to increase Dox resistance and this
was associated with evidence of autophagy. Anti-HMGB1 neutralizing antibody significantly reduced the effect of
extracellular HMGB1 released from dying cancer cells or of recombinant HMGB1 on Dox resistance.
Conclusions: These findings highlight the potential of stromal fibroblasts to contribute to chemoresistance in
breast cancer cells in part through fibroblast-induced HMGB1 production.
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Breast cancer is the most common cancer in females
worldwide [1] including Thailand [2]. The standard treat-
ment of breast cancer patients is surgery and chemother-
apy. Chemotherapy can be used before (neoadjuvant) or
after surgery, with or without other interventions, e.g. radi-
ation or targeted therapy, depending on the subtype and
stage of the disease [3]. Unresponsiveness to chemothera-
peutic drugs, however, is still the main problem. It has
been reported that about 30% of early stage breast cancer
patients have a risk of developing drug resistance and can-
cer recurrence [4]. Resistance is primarily due to the in-
herent genetic instabilities of cancer cells; however, the
resistance acquired during cancer progression and in par-
ticular the role of the tumor microenvironment, has also
been investigated [5]. A variety of bioactive molecules are
secreted by fibroblasts in the tumor microenvironment
which can promote tumor growth, metastasis, neoangio-
genesis and drug resistance [6-8]. Interactions between
cancer cells and stromal fibroblasts reportedly contribute
to the chemoresistance of pancreatic ductal adenocarcin-
oma. The mechanisms described include epigenetic regula-
tion of apoptotic genes in cancer cells [9] and the increased
secretion of nitric oxide leading to release of interleukin-1β
by the tumor cells that provides protection from antican-
cer drugs [10].
Moreover, activated fibroblasts in breast cancer have
been correlated with the aggressiveness of the disease
[11-14] and the induction of acquired chemoresistance
[15]. The stromal gene expression pattern has revealed
the potential to predict resistance to preoperative chemo-
therapy with 5-fluorouracil, epirubicin and cyclophospha-
mide [16]. Collagen type I secreted by fibroblasts can
decrease chemotherapeutic drug uptake into cancer cells
leading to the regulation of the response to several agents
[17]. In addition, critical roles of fibroblasts have been de-
scribed in tamoxifen resistance via activation of growth
factor-related signaling pathways or increased mitochon-
drial function resulting in an anti-apoptotic effect [18,19].
Taken together, this evidence suggests that targeting
stromal fibroblasts and mechanisms by which cancer-
associated fibroblasts are activated may be an emerging
novel therapeutic strategy for breast cancer.
High mobility group box 1 (HMGB1) or amphoterin is
a chromatin-associated nuclear protein. It has also been
recognized as an extracellular "damage-associated mo-
lecular pattern" (DAMP) molecule, which has been de-
tected in several diseases including cancer [20]. HMGB1
can be produced by both tumor cells and stromal cells
and is released into the extracellular environment from
stressed and dying cells [21]. HMGB1 can be released
passively from dying tumor cells after chemotherapeutic
treatment [22] or following tumor cell lysis by the action
of lymphokine-activated killer cells, [23]. In contrast, somestudies have reported active secretion of HMGB1 from
certain types of cancer [24,25]. Several chemotherapeu-
tic agents used in the treatment of breast cancer includ-
ing cyclophosphamide, methotrexate, paclitaxel [22]
and doxorubicin [26] induce HMGB1 release into the
tumor microenvironment following cell death. More-
over, radiotherapy has also been shown to induce the re-
lease of HMGB1 [26]. Finally, it has been shown that host
cells, in particular neutrophils and macrophages, are acti-
vated by cytokines as part of an innate immune response
to cancer cells and actively secrete HMGB1 [27].
Interestingly, factors diffusing from stromal fibroblasts
have recently been shown to up-regulate intracellular
HMGB1 in lung cancer cells [28]. HMGB1 may then
be released from cancer cells during radiotherapy or
chemotherapy and act upon surviving cancer cells to
promote regrowth and metastasis [29]. Hence we hypothe-
sized that stromal fibroblasts in breast cancer may also play
a similar role in chemoresistance through the up-regulation
of HMGB1 in cancer cells during chemotherapy-mediated
cell death. This study aimed to explore the effect of se-
creted substances from breast cancer-associated fibro-
blasts (BCFs) on HMGB1 expression in breast cancer
cells and the potential of extracellular HMGB1 to influ-
ence chemosensitivity.
Methods
Breast cancer cell culture
The human breast cancer cell line MDA-MB-231 was
obtained from ATCC-LGC (#HTB-26, Middlesex, UK).
Cells were cultured in DMEM (Gibco, Grand Island, NY,
USA) supplemented with 10% fetal bovine serum (FBS;
Gibco), 100 U/ml penicillin, 100 μg/ml streptomycin
(Gibco), and anti-fungal agent. Cells were cultured in a
5% CO2 in air incubator at 37°C and passaged by 0.25%
trypsin-EDTA when they reached confluence. Cells of
more than 90% viability evaluated by trypan blue dye ex-
clusion were used in further experiments.
Primary cultures of human fibroblasts
Primary cultures of breast cancer-associated fibroblasts
(BCFs) were isolated from patients who underwent sur-
gery at Siriraj Hospital, Mahidol University, Bangkok, and
non-tumor-associated fibroblasts (NTFs) were isolated
in each case from adjacent uninvolved breast tissue. The
protocol for tissue collection was approved by the Siriraj
Institutional Review Board (si498/2010) and informed
consent was obtained from each of the six patients en-
rolled for this study. All breast cancers were of the hor-
mone receptor positive luminal subtype. Briefly, sterile
fresh surgical tissue was placed on ice in DMEM/F12
(Gibco) supplemented with 10X penicillin-streptomycin
(1,000 U/ml penicillin and 1,000 μg/ml streptomycin)
(Gibco). Tissues were washed 2 to 3 times by 1X phosphate
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sues were then minced finely using a sterile surgical blade
followed by enzymatic dissociation in collagenase type 1A
(1,140 U/ml) (Sigma-Aldrich, St. Louis, MO, USA) diluted
in DMEM/F12 supplemented with 10% FBS for 2 h at
37°C with agitation every 20 min. Next, tissues were
digested in 0.05% trypsin-EDTA (Gibco) in serum-free
DMEM/F12 for 10 min. The digestion solution was re-
moved and fragments were washed with DMEM/F12
containing no FBS. The cell suspension was sequentially
filtered through 100 μm and 70 μm nylon meshes (BD
Biosciences, San Jose, CA, USA) and centrifuged at 2,000 xg
for 5 min. The cell pellet was resuspended in complete
DMEM/F12 media and cultured in a 25 cm2 culture flask
(Corning, NY, USA). Cells isolated from tissue samples
were incubated in DMEM/F12 media containing 10% FBS
for 10–14 days to allow attachment and the formation of
colonies; these primary cultures were designated as pas-
sage 0. All cultures were kept in a humidified incubator
with 5% CO2 in air at 37°C. Cells were subcultured when
80% confluent, banked and used for characterization and
experimental studies at passages 5–13.
Immunocytochemistry of BCFs and NTFs
To discriminate BCFs and NTFs from cancer cells, immu-
nohistochemical staining for epithelial CK19 and mesen-
chymal ASMA markers were performed. The breast cancer
cell line, MDA-MB-231 was used as a positive control for
CK19 detection. In brief, around 4,000 cells were plated
into each well of a 96-well plate and cultured for 24-h to
allowed for cell adhesion. Cells were then fixed with 4%
paraformaldehyde. Non-specific binding was blocked by in-
cubating cells with 1% BSA in 1X PBS for ASMA detection
or 5% FBS in 1X PBS for CK19 detection. Mouse anti-
human CK19 antibody (SC-6278; 1:100 dilution, Santa
Cruz Biotechnology Inc., Dallas, TX, USA) or mouse
anti-human ASMA antibody (A5228, 1:200 dilution,
Sigma-Aldrich) was added for 3 h at room temperature. A
blocking reagent was used as the negative control in place
of the primary antibody. After washing with 1X PBS, goat
anti-mouse IgG-Cy3 antibody (#115-166-071, 1:2,000,
Jackson ImmunoResearch Laboratories Inc, West Grove,
PA, USA) was applied for 1 h at RT. The signals were de-
tected by fluorescence microscopy.
Collection of fibroblast conditioned-media
Cultures of BCF and NTF were grown in 75-cm2 flasks
to reach 90-95% confluency in DMEM (containing 10%
FBS) which is a suitable media for MDA-MB-231 cells.
The conditioned-media (CM) were collected 24 h fol-
lowing addition of fresh complete medium and desig-
nated as 24-h CM. CMs were centrifuged at 2,000 g for
5 min to remove cell debris and the suspension stored
at −80°C or −20°C until use.Scratch wound tumor cell motility assay
MDA-MB-231 cells were cultured in a 6-well plate until
approximately 90-100% confluent. A reference line was
drawn across the bottom of the plate. A scratch wound
was made in the cell monolayer with a sterile 200-μl pip-
ette tip and the culture was then washed three times
with serum-free medium to remove the detached cells.
The cells were then treated with BCF-CM, NTF-CM or
complete medium as a negative control. The scratch wound
indicated by the reference line was imaged at the start of
the treatment and 6 h later. The cell migration efficiency
was determined as a percentage of wound healing calcu-
lated by the following formula using three different zones
for each condition:
% wound closure ¼ wound width at 0 h−wound width at 6 hð Þ  100
wound width at 0h
Real time PCR for HMGB1 mRNA detection
Total RNA was extracted from MDA-MB-231 breast
cancer cells using the PerfectPure RNA Cultured Cell
Kit (5 Prime; Gaithersburg, MD, USA) as per the manu-
facturer’s instructions. The OD260/280 and OD260/230
were measured to ensure the quality of extracted RNA.
Complementary DNA was synthesized from 1 μg of total
RNA using the SuperScript™ III First-Strand Synthesis
System for RT-PCR (M-MLV) (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Ex-
pression levels of HMGB1 were determined by SYBR
Green-based real time PCR (Roche Applied Sciences, In-
dianapolis, IN, USA) in a Light Cycler® 480 II machine
(Roche Applied Sciences). Optimal primers were de-
signed using the nucleotide database in PubMed and
Primer 3 software. Sequences of primers were: HMGB1
(NM_002128.4): forward primer: 5'-CACTGGGCGAC
TCTGTGCCTCG-3', reverse primer: 5'-CGGGCCTT
GTCCGCTTTT-GCCA-3'. β-actin (ACTB) served as
an internal control to adjust the amount of starting
cDNA. The expression of each gene in breast cancer
cells was calculated by the 2-ΔCp equation. In this case,
ΔCp= Cp(HMGB1) - Cp(ACTB). The expression of
HMGB1 in breast cancer cells treated with fibroblast
CM or doxorubicin (Dox) (Pfizer, Perth Pty Ltd, Bent-
ley WA, Australia) compared with that in untreated
control cells was calculated by the 2-ΔΔCp equation. In this
case, ΔCp= Cp(HMGB1) - Cp(ACTB) and ΔΔCp= ΔCp
(treated cells) - ΔCp(control cells).
Western blot analysis
MDA-MB-231 breast cancer cells were treated with
BCF-CM or NTF-CM for 48 hr. Cell suspensions were
centrifuged at 2,000 ×g for 5 min in a refrigerated cen-
trifuge. The cell pellets were collected and rinsed in cold
1X PBS twice before lysis in 1X sample buffer containing
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5% (v/v) β-mercaptoethanol and 0.05% (w/v) bromophenol
blue. Cell lysates were boiled for 10 min and centrifuged
at 10,000 rpm for 1 min to remove undissolved proteins
and cell debris. Cell extracts were then separated by
10% SDS-PAGE and transferred onto PVDF membranes
(GE Healthcare, Buckinghamshire, UK). Membranes were
blocked in 5% skimmed milk containing TBST (TBS
containing 0.1% Tween 20) for 1 h at room temperature.
Membranes were then washed 3 times with 1X TBST
and incubated with 1:1,000 rabbit anti-human HMGB1
(ab18256, Abcam, Cambridge, CB4 OFL, UK) at 4°C
overnight. After washing, membranes were incubated
with 1:2,000 goat anti-rabbit IgG-HRP (Abcam) at room
temperature for 1 h. The blots were visualized by en-
hanced chemiluminescence (Thermo Scientific, Rockford,
IL, USA). Using 1:10,000 anti-β-actin antibody (sc47778,
Santa Cruz Biotechnology Inc.) or 1:10,000 anti-β-actin
antibody (ab8226, Abcam) with the suitable HRP conju-
gated secondary antibody, β-actin protein levels were used
as an internal control to confirm equal protein loading.
β-actin normalized HMGB1 levels in breast cancer
cells without any CM treatment were used as controls.
The same procedure was used for the measurement of
extracellular HMGB1 except for the process of sample
collection. To measure the amount of HMGB1 released
from cells, the media from cells stimulated with either
BCF-CM or NTF-CM were collected and concentrated
using a 10 kDa cut-off Vivaspin concentrator (Sartorius
Stedim Biotech, Goettingen, Germany) at 3,500 ×g. Protein
concentration was determined by a Coomassie Plus
(Thermo Scientific) assay kit. The same amount of
total protein was loaded into SDS-PAGE gels and the
procedure for detection of HMGB1 above.
For LC3B autophagy protein detection, cells were
treated with 100 ng/ml human rHMGB1 (#1690-HMB-
050, R&D Systems, Minneapolis, MN, USA) with or
without anti-HMGB1 neutralizing antibody (H00003146-
M08, Novus, Littleton, CO, USA) before exposure to
Dox for 24 h. Cells were harvested and total proteins
were separated and blotted on to the membrane as de-
scribed above. The rabbit anti-human LC3B (#2775,
Cell Signaling Technology, Danvers, MA, USA) was
then incubated at 1:2,000 dilution with the membranes
at 4°C overnight followed by goat anti-rabbit IgG-HRP
(#7044, Cell Signaling Technology; 1:1,200 dilution) at
room temperature for 1 h. The blots were visualized as de-
scribed previously.
Treatment of MDA-MB-231 breast cancer cells with
doxorubicin or conditioned-media
MDA-MB-231 breast cancer cells were cultured in 6-well
plates (3 × 105/well) for 48 h, then the growth medium
was removed and the cells washed thoroughly with PBS.CM from either BCF or NTF was added to the cells which
were incubated for a further 48 h at 37°C in a 5% CO2 in
air incubator. Negative controls were cultured in parallel
in DMEM plus 10% FBS. Cells were then harvested to de-
termine the level of intracellular HMGB1 expression by
real time PCR and Western blot analysis. At the same
time, the culture media were also collected to investigate
the level of extracellular HMGB1. Similarly, 1 and 5 μM
doxorubicin Dox (Pfizer) was used to treat MDA-MB-231
breast cancer cells for 48 h. Dox-treated cells were har-
vested to determine the level of intracellular HMGB1
by real time PCR and the culture medium was also col-
lected to investigate the level of extracellular HMGB1. In
addition, cancer cells with or without pre-treatment with
fibroblast CMs were then exposed to Dox for 48 h to in-
duce cell death and the release of HMGB1. Cell viability
was checked by trypan blue exclusion and the levels of
HMGB1 were determined by Western blot analysis as
above.
Response of breast cancer cells treated with recombinant
HMGB1 to Doxorubicin
MDA-MB-231 cells were seeded into 96-well plates at
6,000 cells per well and cultured overnight in DMEM +
0.1% FBS. Cells in triplicate wells were then treated
with 100 ng/ml rHMGB1 (R&D Systems) in the presence
or absence of 10 mg/ml HMGB1-neutralizing antibody
(Novus) and then 5 μM Dox or vehicle. Cell viability was
measured 24 h later by trypan blue exclusion.
Effect of CM on Dox sensitivity of MB-231 breast cancer
cells
MDA-MB-231 cells were plated at a density of 6,000
cells/well in 96-well plates. These cells were treated for
24 h with CM collected from MDA-MB-231 cells exposed
to 5 μM Dox (for 48 h), designated as ‘dead cancer-CM’,
with or without anti-HMGB1-neutralizing antibody
(10 mg/ml) or isotype-matched control IgG (X0943,
Dako, Agilent Technologies, Glostrup, Denmark). Cell
viability after exposure to 5 μM Dox was analyzed by
erythrosine B dye exclusion and compared with control
untreated cells. Three independent experiments were
performed.
Statistical analysis
The values are expressed as mean ± SD. Statistical sig-
nificance was determined by Student’s t-test. A p-value
of equal to or less than 0.05 was defined as statistically
significant.
Results
Characterization of primary cultures of BCFs and NTFs
BCFs and NTFs were characterized by their expression
of the mesenchymal marker, ASMA, and absence of the
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revealed that all cancer-associated and ‘normal’ breast fi-
broblasts from six different patients were negative for
CK19 compared with the positive control MDA-MB-231
breast cancer cells (Figure 1) and were positive for
ASMA. Thus we confirmed that both BCFs and NTFs
were mesenchymally-derived cells with no epithelial cell
contamination.
To ensure that the BCFs were activated and capable of
promoting malignant potential, the effects of CM on
MDA-MB-231 breast cancer cell migration were tested.
The results indicated that the BCF-CM promoted cancer
cell migration to a significantly greater degree than
NTF-CM (Figure 2). Indeed, NTF-CM had a minimal
effect compared with untreated control cells.Figure 1 Immunofluorescent staining of CK19 and ASMA in primary c
adjacent areas of normal breast from surgical specimens (NTF). BCF 0
NTF are matched normal tissue fibroblasts pooled from patients 037 and 0
for CK19. Hoechst (blue) staining shows the nuclei. Original magnification oIncreased expression of HMGB1 in breast cancer cells
treated with fibroblast-derived CM
BCF-CM significantly induced intracellular HMGB1
protein expression in MDA-MB-231 breast cancer cells
as detected by Western blot analysis at all time points
tested (Figure 3). The effect was time-dependent and
since the greatest differential induction (BCF-CM vs
NTF-CM) was observed at 48 h, this time period was se-
lected for further studies. As a further quality control,
the CMs of BCF and NTF isolated from the same pa-
tient were used to treat MDA-MB-231 cells and HMGB1
gene expression was analyzed by real time PCR. The re-
sults showed that BCF-CM induced HMGB1 mRNA to
a significantly greater degree than NTF-CM (Figure 4A).
Western blot analysis confirmed that the protein levelsultures of fibroblasts derived from breast cancers (BCF) and
16, BCF 037 and BCF 044 are derived from different patients, whereas
44. Breast cancer cell line MDA-MB-231 was used as a positive control
f 400x. Bars represent 20 μm.
Figure 2 BCF-CMs enhance MDA-MD-231 cell migration. MDA-MB-231 breast cancer cells were exposed to 3 different BCF-CMs and
pooled samples of 5 NTF-CMs and a scratch wound motility assay was performed over 6 h to measure the ability of CM to induce
cancer cell migration. Bar graphs represent mean ± SD of two independent experiments. The migration of cells in control fresh media (Ctl) was
set at 100%. * = p-value of less than 0.05 compared to the migration of cancer cells under control conditions. ns = not significance.
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cantly higher than those induced by patient-matched
NTF-CM (Figure 4B). In addition, HMGB1 protein levels
in MDA-MB-231 cells treated with BCF-CMs from differ-
ent patients were consistently significantly higher than
those treated with NTF-CMs.
Cell death induced by Dox promotes expression and
release of HMGB1
Doxorubicin is commonly used in breast cancer treat-
ment and our results using real time PCR showed that
this drug could induce intracellular HMGB1 expression in
MDA-MB-231 cells in a concentration-dependent manner
(Figure 5A). The maximal level of HMGB1 was induced
with 5 μM which was statistically significantly different
from untreated controls. Moreover, cancer cells killed
by Dox exposure released HMGB1 into the culture
media and the level was again increased in a concentration-
dependent manner (Figure 5B).BCF-CM-pretreated cancer cell cultures showed less
cell death in response to Dox than cells pre-treated with
NTF-CM (Figure 5C). In a second study, we found that
BCF-CM treated cells also released more HMGB1 than
those pre-treated with NTF-CM when treated with equi-
toxic concentrations of Dox (80% cell death) (Figure 5D).
No HMGB1 was detected in the culture media when cell
viability was greater than 95% but in contrast, Dox-
induced release of HMGB1 was related to the degree of
cell death (data not shown).Recombinant HMGB1 alters Dox sensitivity via autophagy
MDA-MB-231 cells exposed to Dox together with
rHMGB1 showed statistically significantly higher viability
than those treated with Dox alone (Figure 6A). This effect
was reversed by the addition of an HMGB1 neutralizing
antibody. The fact that LC3B-I converts to LC3B-II
and levels of LC3B-II increase over time suggests that
Figure 3 Western blot analysis of intracellular HMGB1 in MDA-MB-231 human breast cancer cells treated with fibroblast CMs (BCF 044
and NTF 044) for 6, 24, and 48 h. Cancer cells cultured in fresh medium were used as a negative control. The intensity of each HMGB1 band is
shown after normalization against the β-actin internal loading control protein. Bar graphs represent mean ± SD of two independent experiments.
* = p-value of less than 0.05 comparing HMGB1 levels in the CM-treated cells with controls at each time point; # = p-value of less than 0.05
comparing HMGB1 levels in BCF-CM-treated cells with NTF-CM treatment.
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rHMGB1 (Figure 6B).
Dead cancer cell CM attenuates the effects of Dox on
MDA-MB-231 breast cancer cell viability in part via
HMGB1
Dead cancer-CM, (shown to increase the level of extra-
cellular HMGB1; Figure 5B) also increased the survival
of MDA-MB-231 cells during subsequent Dox treatment
(Figure 6C) and this effect was reversed by an HMGB1
neutralizing antibody (**p-value = 0.006). The blocking
antibody also showed a small but significant reduction
in cell viability in the absence of CM (p-value = 0.017).
Discussion
One of the main reasons for treatment failure in breast
cancer is acquired drug resistance. The interaction of
tumor cells with their microenvironment has been fre-
quently reported to influence cancer progression and
drug resistance [5,7,30]. Tumor-associated stromal cells
have been shown to protect tumor cells from cell death
and the cytotoxic effects of chemotherapeutic drugs
[31,32]. Recently, the impact of cancer-associated fibro-
blasts on the expression and localization of HMGB1 in
lung cancer cells has been demonstrated to operate via
the release of diffusible factors from fibroblasts [28]. Theextracellular HMGB1 protein behaves as a cytokine, pro-
motes inflammation and participates in the pathogenesis
of several disorders in peripheral organs. Extracellular
HMGB1 has potential impact in the induction of drug
resistance and has been proposed as an immunotherapeu-
tic target to modulate chemotherapeutic responses [22].
Activated fibroblasts in breast cancer tissues have been
identified in several reports [11,15]. In invasive ductal
carcinoma, metastatic ability is closely related to the
proliferation of fibroblasts [12]. To clearly understand
the biological function of fibroblasts in cancer tissues,
primary cultures of human fibroblasts are critical. The
identity of primary NTFs and BCFs was confirmed here
by ASMA positivity [33,34]. All breast cancer tissues
used for isolation of primary cultures of fibroblasts in
this study were of luminal subtype and positive for es-
trogen receptor and/or progesterone receptor. The ab-
sence of the CK19 epithelial marker was taken as an
indication that the fibroblasts were not cancer cells that
had undergone an epithelial-to-mesenchymal transition
(EMT). This is supported by the evidence that EMT is
most common in basal-like breast cancers [35] and loss
of CK19 is rare in hormone receptor-positive breast can-
cer tissues [36]. ASMA can be used to indicate that the fi-
broblasts are myofibroblasts but cannot determine their
tumor-promoting potential. Cancer-associated fibroblasts
Figure 4 HMGB1 expression in MDA-MB-231 cells treated with
fibroblast CM. Real time PCR for HMGB1 expression in MDA-MB-231
cells treated with NTF-CMs and BCF-CMs for 48 h using paired
fibroblasts isolated from the same patient.The levels of HMGB1
transcript (A) and protein levels (B) are shown after normalization
against the internal control β-actin. Controls (Ctl) are cells cultured
in fresh medium with no CM treatment. Bars represent the mean ± SD
of triplicate experiments. $ = p-value of less than 0.05. * = p-value of
less than 0.05 compared to the average HMGB1 of the two NTFs-CM
treatment conditions whereas # = p-value of less than 0.05 compared
to HMGB1 of the matched NTF-CM treatment.
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tumorigenic molecules and to promote cancer progression
[8,37]. We used the ability of the BCF-CM to promote
breast cancer motility in a scratch wound assay as an indi-
cator of their activated phenotype.
The present study confirmed the effect of fibroblast-
derived substances in enhancing HMGB1 expression in
human breast cancer cells. Primary cultures of fibro-
blasts isolated directly from breast cancer tissues (and
with patient-matched control cells) were used in prefer-
ence to established fibroblast cell lines for greater clin-
ical relevance. Cancer cells exposed to fibroblast CM
showed increased survival in response to a standard che-
motherapeutic agent, doxorubicin. This protective effect
correlated with the increased level of HMGB1 releasedfrom the cells, was mimicked by recombinant HMGB1
and reversed by the HMGB1 blocking antibody. These
observations suggest that cancer-associated fibroblasts
should be considered as a possible therapeutic target
to attenuate acquired chemoresistance in breast cancer
patients via activation of HMGB1.
Interestingly, the CM derived from BCFs induced the
production of HMGB1 in cancer cells in a time-
dependent manner to a significantly greater degree than
the CM from NTFs derived from adjacent non-involved
breast tissue in the same patient. These results are in
agreement with a previous report using lung fibroblast
CMs to activate HMGB1 production in lung cancer cells
[28]. From this study, the small amount of actively
released HMGB1 detected under control conditions
(with no diffusible factors from fibroblasts) was as-
cribed to necrotic cell death in vitro.
It is well known that monocytes and macrophages can
actively secrete HMGB1 in response to various stress
stimuli [27]. Although some cancer cells have the ability
to secrete HMGB1 into the culture media, these are lim-
ited and include colon cancer and malignant mesothelioma
[24,25,38]. Alternatively, HMGB1 release can be induced
by hypoxia [39] or inflammatory cytokines [40]. In breast
cancer tissues investigated by immunohistochemistry, it
is possible that phosphorylated HMGB1 may reside in
the cytoplasm which corresponds to our observations of
increased cytoplasmic HMGB1 in breast cancer tissues
(data not shown).
HMGB1 is overexpressed in many types of cancer
[41-45] including breast cancer [46-48]. In addition to
this intrinsic expression, breast cancer cells can be stim-
ulated by factors released from activated fibroblasts to
increase their expression of HMGB1. When these cancer
cells die after cytotoxic treatment, extracellular HMGB1
is detected in proportion to the levels of intracellular
HMGB1. In the present study, MDA-MB-231 breast
cancer cells were induced by BCF-CMs (or by Dox) to
express high levels of HMGB1.When cell death was in-
duced, HMGB1 could be subsequently released. It can
be hypothesized that HMGB1 could then act upon sur-
rounding cancer cells to induce a degree of resistance to
chemotherapeutic agents. In support of our findings,
extracellular HMGB1 has been shown by Luo et al. to
stimulate the regrowth and metastasis of cancer cells
that survived prior chemotherapy [29].
Using ‘dead cancer-CM’, our results indicate that HMGB1
may be one component released by dying cells that can in-
fluence the response of other cancer cells to Dox. How-
ever, the viability of breast cancer cells could not be
completely rescued by an HMGB1 neutralizing antibody,
implying that other substances released from dead cancer
cells may be responsible for Dox resistance. Extracellular
HMGB1 binds to the ‘receptor for advanced glycation end
Figure 5 Dox-induced HMGB1 in MDA-MB-231 cells. (A) Intracellular HMGB1 expression was measured by real time PCR. Bars represent mean ± SD
of HMGB1 expression level normalized against ACTB and relative to no drug treatment. Three independent experiments were performed. (B) Extracellular
HMGB1 protein was detected by Western blot analysis in the culture media from cells treated with different concentrations of Dox for 48 h. (A and B)
*p-value of less than 0.05 compared to the controls without Dox treatment. (C) BCF-CM induced resistance to Dox-mediated cell death in MDA-MB-231
breast cancer cells. Bars represent % cell death of each pre-treatment condition and the images show corresponding cell density. (D) Culture media from
each condition in (C) were measured for extracellular HMGB1 by Western blot analysis. Equal amounts of proteins were loaded. Bars represent the mean
band intensity (± SD) measured by densitometry. The band intensity of control cultures without CM pre-treatment (Ctl) was set as 1. *p-value of
less than 0.05.
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However, HMGB1 can promote 3T3 fibroblast wound
healing by inducing cell proliferation and migration, and
this effect occurs through the activation of the RAGE/
MEK/ERK pathway [50]. HMGB1 caused concentration
and time-dependent increases of IL-6 production via
RAGE, c-Src, Akt, p65, and NF-κB signaling pathways
[51]. Although the pathways activated by extracellular
HMGB1 in breast cancer cells have not been identified,
they may lead to the induction of cancer progression
and drug resistance. The ability of released HMGB1 to
trigger drug resistance in cancer cells is reportedly due
to autophagy [52,53]. In addition, autophagy can alsoplay a role in anthracycline resistance in triple-negative
breast cancer (TNBC) [54]. This is supported by our
findings that HMGB1 was linked to autophagy and Dox
resistance in TNBC MDA-MB-231 cells.
The data reported here indicate the potential of extra-
cellular HMGB1 released from breast cancer cells to exert
a paracrine effect on surviving cancer cells enabling them
to resist Dox therapy. An anti-HMGB1 antibody or
specific inhibitor (i.e. glycyrrhizin) [55] or targeting its
proposed receptors (RAGE and the toll-like receptor 4,
TLR4) on cancer cells may prevent or inhibit the develop-
ment of drug resistance. In contrast, there is the evidence
that chemotherapeutic drug-induced HMGB1 can mediate
Figure 6 Effect of recombinant HMGB1 (rHMGB1) on the
response of MDA-MB-231 to Dox. (A) MDA-MB-231 human breast
cancer cells were treated with 5 μM Dox with or without addition of
100 ng/ml rHMGB1 and/or anti-HMGB1 neutralizing antibody for 24 h.
The % cell viability is shown and the bars represent the mean ± SD
of triplicate experimental wells. (B) Autophagy-related protein LC3B
is induced in MDA-MB-231 breast cancer cells. Densitometric
analysis of LC3B-II normalized against the protein loading control
β-actin and the conversion of LC3B-I to LC3B-II is shown. (C) MDA-
MB-231 cells treated with ‘dead cancer-CM’ showed increased
viability compared with controls and this effect was attenuated by
anti-HMGB1 neutralizing antibody. Bars represent mean ± SD of
three independent experiments. * = p-value of less than 0.05
whereas ** is less than 0.01.
Figure 7 Schematic diagram illustrating the potential of
secreted substances from breast cancer-associated fibroblasts
(BCFs) to induce expression of intracellular HMGB1 in breast
cancer cells. After exposure to a chemotherapeutic agent, in this
case doxorubicin, (Dox), this increased intracellular HMGB1 can be
released and may function in a paracrine manner to induce acquired
chemoresistance of the nearby surviving cancer cells.
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[56]. Thus caution must be exercised, given the potential
positive and negative aspects of HMGB1 expression at dif-
ferent phases of tumor development and during treatment.
Conclusions
The findings reported here highlight the potential of
cancer-stromal fibroblast interactions to drive chemore-
sistance in breast cancer in part as a result of fibroblast-
induced HMGB1 production and release into the tumor
microenvironment with paracrine effects on neighbor-
ing cancer cells (Figure 7). To support this hypothesis,circulating HMGB1 levels could be tested as a predictor
of responses to neo-adjuvant chemotherapy in breast
cancer patients [57]. High levels of serum HMGB1 in
patients have been correlated with drug resistance
whereas low HMGB1 indicated sensitivity. Targeting
cancer-associated fibroblasts which have more genetic
stability than cancer cells is an alternative therapeutic
approach [30] to interrupt the cycle of fibroblast-induced
HMGB1 in mediating acquired chemoresistance.
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